Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-1017
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-09-08T06:06:48.970598Z
status: published
lens: p_space
sector: health
headline: From Correlation to Clinical Translation: The Biological-Grounding×Translational-Readiness Framework for Artificial Intelligence in Non-Small-Cell Lung Cancer
dek: Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer death worldwide, and clinicians now face a rapidly expanding array of artificial intelligence (AI) tools promising earlier detection, better treatment selection, and more precise radiotherapy, yet few have altered what happens at the bedside. The problem is not poor benchmark performance; it is that strong benchmark performance has repeatedly failed to translate into demonstrable patient benefit, because most published NSCLC models are retros…
gain_title: (none)
problem_title: In non-small-cell lung cancer, AI tools show strong benchmark performance but have repeatedly failed to translate into patient benefit because most models are retrospective, single-center, and validated only on metrics that do not track survival, toxicity, or procedural burden.
trace_subject: (none)
gain_reading: (none)
gain_evidence: (none)
problem_reading: In non-small-cell lung cancer, AI tools show strong benchmark performance but have repeatedly failed to translate into patient benefit because most models are retrospective, single-center, and validated only on metrics that do not track survival, toxicity, or procedural burden.
problem_evidence: strong benchmark performance has repeatedly failed to translate into demonstrable patient benefit | most published NSCLC models are retrospective, single-center, and validated only against metrics that do not track survival, toxicity, or procedural burden
quick_read: This peer-reviewed review examines why AI tools for non-small-cell lung cancer, despite promises of earlier detection and more precise treatment selection and radiotherapy, have rarely changed bedside care. It introduces the biological-groundingd7translational-readiness matrix to map each model on biological grounding and lifecycle validation and to specify the next study needed for clinical advancement.

The framework matters because it reframes success from benchmark metrics to patient-centered outcomes like survival and toxicity, highlighting that the most biologically grounded models are rarely the most clinically validated. Uncertainty remains about whether proposed solutions d spatial transcriptomics grounding, federated multi-institutional validation, and prospective adaptive trials d will actually deliver longer, less toxic survival, as the review does not report new prospective outcome data.
limitation: 
tag: Evidence-backed problem
key_points: Review introduces biological-groundingd7translational-readiness matrix to locate any NSCLC AI model along two axes and identify next study needed. | Analysis across nodule detection, histopathologic and molecular inference, prognostic stratification, radiotherapy planning, immunotherapy response prediction, and surveillance finds most biologically grounded models are rarely most clinically validated. | Authors propose spatial transcriptomics as mechanistic ground-truth platform and call for federated multi-institutional validation and prospective adaptive trials measured by survival and toxicity, not AUROC.
rundown: The review surveys AI across the NSCLC continuum from nodule detection to disease surveillance and finds a systematic mismatch: models optimized for AUROC and other benchmarks are typically retrospective and single-center, without validation against survival or toxicity.

To address this, it defines the BGd7TR matrix, arguing that biological grounding and lifecycle validation are orthogonal deficits, and proposes spatial transcriptomics as ground truth plus federated validation and prospective adaptive trials to advance models toward longer, less toxic survival.
sources:
- peer_reviewed | American Journal of Clinical Oncology | https://doi.org/10.1097/coc.0000000000001370 | 2026-09-07
prev: 0000000000000000000000000000000000000000000000000000000000000000

sha256

a9ec7d0bbdc45d6c8e4b49269db7d1c0be429e65bc881bc5ab62d353c2de9a28

previous

0000000000000000000000000000000000000000000000000000000000000000